Brentuximab vedotin retreatment in patients with cutaneous T-cell lymphoma: a pooled analysis of real-world studies
European Journal of Cancer · 2025-10 · 229
DOI: 10.1016/j.ejca.2025.115984 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2025-10. Verfasst von Christina Mitteldorf und 12 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Mitteldorf, C., Masson, A. D., Beylot-Barry, M., Gutiérrez, A., Domingo-Domènech, E., Barca, E. G., Muniesa, C., Ortiz-Romero, P. L., Baeza, L., Stache, V., Garcıá-Sanz, R., Assaf, C., & Sureda, A. (2025). Brentuximab vedotin retreatment in patients with cutaneous T-cell lymphoma: a pooled analysis of real-world studies. European Journal of Cancer, 229. https://doi.org/10.1016/j.ejca.2025.115984
Vancouver
Mitteldorf C, Masson AD, Beylot-Barry M, Gutiérrez A, Domingo-Domènech E, Barca EG, et al. Brentuximab vedotin retreatment in patients with cutaneous T-cell lymphoma: a pooled analysis of real-world studies. European Journal of Cancer. 2025;229. doi:10.1016/j.ejca.2025.115984
BibTeX
@article{Mitteldorf2025,
author = {Mitteldorf, Christina and Masson, Adele de and Beylot-Barry, Marie and Gutiérrez, Antonio and Domingo-Domènech, Eva and Barca, Eva Gonzalez and Muniesa, Cristina and Ortiz-Romero, Pablo L. and Baeza, Lourdes and Stache, Vanessa and Garcıá-Sanz, Ramón and Assaf, Chalid and Sureda, Anna},
title = {Brentuximab vedotin retreatment in patients with cutaneous T-cell lymphoma: a pooled analysis of real-world studies},
journal = {European Journal of Cancer},
year = {2025},
volume = {229},
doi = {10.1016/j.ejca.2025.115984}
}
EUVIMED